LCBs are non-inferior to PCBs for treating coronary ISR, with similar clinical outcomes. Supports LCBs as a viable alternative. #Biolimus #MetaAnalysis #Paclitaxel #Sirolimus
link.springer.com/article/10.1...
4
0
0
0
LCBs are non-inferior to PCBs for treating coronary ISR, with similar clinical outcomes. Supports LCBs as a viable alternative. #Biolimus #MetaAnalysis #Paclitaxel #Sirolimus
link.springer.com/article/10.1...